The Effect of Erythropoietin Administration on the Serum Level of YKL-40, pro-BNP and IL-6 in Coronary Surgery Patients

Mahnoosh Foroughia, Zohre Mohammadi2, Masoud Majidi Tehrani3, Mahmood Bakhtiari4, Ali Dabbagh* and Mostafa Haji Molahoseini 4

aCardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. bClinical Research and Development Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. cAnesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. dDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

* Corresponding author:
E-mail: alidabbagh@sbmu.ac.ir

Abstract

Cardiopulmonary bypass and aortic clamping evokes the obligatory global myocardial ischemia and dysfunction with a significant inflammatory response. The discrepancy about cardioprotective effects of erythropoietin still exist. The aim of this study was to assess the clinical immunomodulatory effects of Erythropoietin (EPO) on serum inflammatory biomarkers (YKL-40, IL-6) and cardiac biomarkers, (pro-BNP, CK-MB and troponin). In this randomized double blind clinical trial, 132 patients admitted for elective coronary surgery with Cardiopulmonary Bypass (CPB) were randomly assigned in one of three groups: 1-group EPO-A (n = 35) infusion of 300 IU/Kg EPO after anesthesia induction and before undergoing CPB; 2- group EPO-CPB (n = 31) the same intervention during CPB; 3- placebo group (n = 66) saline infusion in the same volume. Cardiac enzymes and serum biomarkers were measured at intervals. There was a sharp increase in serum YKL-40 with a 24 h delay after CPB in all groups without significant difference. The increase in serum IL-6 was significant in EPO-CPB group compared with both other groups (p = 0.001 and p = 0.001, respectively). Serum pro-BNP reached maximum level 24 h after operation in all groups; in group A significantly less than others (p = 0.008). CK-MB increased significantly in all groups (p < 0.001), less prominently in CPB-A group (p = 0.03). EPO administration before induced ischemia may be cardioprotective in terms of cardiac biomarkers in patients undergoing CABG with CPB.

Keywords: Coronary artery bypass grafting; Erythropoietin; Inflammation; Ischemia;

Introduction

During cardiac surgical procedures, cardiopulmonary bypass (CPB) is one of the basic ingredients of the procedure. CPB is associated with a systemic inflammatory response and endothelial dysfunction due to artificial surfaces and surgical trauma, leading to ischemia-reperfusion (IR) injury (1-5). Aortic clamping and obligatory global cardiac ischemia affect the susceptible myocardial tissue to more damage. Though a number of measures have been used to defy inflammation, none has proved to be effective in an indisputable way yet (1, 4-8).

Erythropoietin (EPO) has been acknowledged to release from kidney in response to hypoxic condition to stimulate erythropoiesis in bone marrow. Beyond the hematopoietic effects, a bulk of experimental studies suggests a cardioprotective role for EPO against IR injury. In limited clinical
studies, this supportive role of EPO has been investigated during myocardial reperfusion states; both in surgical approach, i.e. coronary artery bypass graft (CABG) and in percutaneous coronary intervention (PCI); however, neither have yielded to a net definitive result (9, 10). EPO as a pleiotropic cytokine with anti-apoptotic and immune-modulatory effects has also been a matter of interest in clinical researches (11, 12).

YKL-40 or Chitinase-3-like protein 1 (CHI3L1), an inflammatory biomarker, has been recently quoted as an inflammatory biomarker in diagnosis, prognosis and cause of some diseases including cardiovascular pathologies. The name YKL-40 comes from the three main N-terminal amino acids, Y (tyrosine), K (lysine) and L (leucine), and also, molecular weight of 40 kDa (13, 14). Interleukin 6 (IL-6) as a pro-inflammatory biomarker and N-terminal pro-B type natriuretic peptide (pro-BNP) released from cardiomyocytes, could be used as a marker of ventricular dysfunction and cardiac surgery outcome (7, 15-18).

The aim of this randomized clinical trial was to assess the effects of EPO infusion in CABG patients by measuring serum levels of four biomarkers: YKL-40, IL-6, pro-BNP and CK-MB.

Experimental

This study was approved by the local ethics committee and registered on the ClinicalTrials.gov (Identifier: NCT02984111) and IRCT.ir (IRCTID: IRCT2016011621087N1). Written informed consent was obtained from all patients before participation.

In this prospective randomized double-blind placebo-controlled clinical trial, at first, 149 patients were included consecutively. Among them, 21 patients were excluded. The remaining 132 patients were randomly distributed into three study groups (Figure 1):

- **EPO-A (i.e. EPO anesthesia):** 300 IU/Kg EPO (PDpoetin®; Pooyesh Daru, Tehran, Iran) diluted in isotonic saline as a total volume of 50 ml and was systemically infused through central venous line in the time interval started after induction of anesthesia and finished just before initiating CPB; n = 35

- **EPO-CPB (i.e. EPO Cardiopulmonary Bypass):** 300 IU/Kg EPO (PDpoetin®; Pooyesh Daru, Tehran, Iran) diluted in isotonic saline as a total volume of 50 mL and was systemically infused through central venous line in the time interval started just in the start of CPB and continued till aortic declamping; n = 31

- **P (Placebo):** a total volume of 50 ml isotonic saline was infused in the time interval started after induction of anesthesia and continued till aortic declamping; n = 66

Sample size determination was based on similar previous trials investigating the protective effect of EPO in the adult coronary artery disease patients (19, 20).

Inclusion criteria was defined as those patients in the study interval referring to the study center with two or more diseased coronary arteries scheduled for elective non-emergent CABG surgery with CPB and cardioplegic arrest for the first time; however, the patients presenting any of the following criteria were excluded: non isolated coronary surgery; combination of CAD and other cardiac pathologies; hemodynamic instability; recent MI; anemia (hemoglobin (Hb) < 11.5 g/dL); renal dysfunction (creatinine > 1.5 mg/dL); previous administration of EPO; hypercoagulable disorders; thromboembolic events; patient’s unwillingness to participate. All the patients, meeting the study criteria were randomly allocated in one of the three study groups; i.e. EPO-A; EPO-CPB and P, using a randomization list of computer program.

Coronary artery bypass using left internal mammary artery for LAD and saphenous vein grafts for other coronary arteries were done in the culprit lesions for all groups by one surgical team. All patients were treated according to a fixed protocol for general anesthesia, CPB set up, surgical techniques and myocardial preservation, that has been already described in detail (8, 21). Mean arterial pressure during CPB was maintained between 60-80 mmHg, adjustment was done with change in pump flow, dose of nitroglycerin or phenylephrine infusion and crystalloid solution. Hemoglobin concentration less than 7 mg/dL during CPB and less than 8 mg/dL before/after CPB were used as transfusion thresholds. All medical
teams were blinded to group allocation; for this purpose, intravenous prepacked syringes were prepared while their contents were not disclosed to anyone but one of the colleagues. Clinical outcomes were the following items: duration of ventilator care; incidence of acute kidney injury (AKI) which was defined as elevation of serum creatinine more than 50% from baseline within 72 h after surgery; the amount of postoperative surgical bleeding; comparison of perioperative transfusion requirement; atrial fibrillation (AF) within 7 days after surgery; postoperative MI, stroke, hypertension crisis, and thromboembolic events.

Laboratory endpoints were the trend of change in both systemic inflammatory and cardiac biomarkers by measuring their serum levels: YKL-40; IL-6; NT-pro-BNP; CK-MB; Troponin-I

Blood sampling for different biomarker measurements was accordingly based on the scheduled biomarker sampling time: before anesthesia induction (T1), at the end of surgery after protamine reversal (T2), the first (T3) and second (T4) postoperative day. The blood samples were centrifuged at 2500 rpm for 15 min within one hour after blood sampling, and the serum was stored at -20 °C until assayed.

YKL-40 concentration was measured by a quantitative ELISA kit (Human Chitinase 3-like1/YKL-40 ELISA Kit, Boster Immunoleader, Boster Biological Technology Co., Ltd. Pleasanton, CA, USA). The concentration of the IL-6 was measured by a colorimetric quantitative ELISA kit (Platinum ELISA, Affymetrix, eBioscience, USA). NT-pro-BNP measurement was done in serum using a commercially available two-site chemiluminescent immunometric assay (IMMULITE 2000 NT-pro-BNP, Siemens Healthcare, Mannheim, Germany), following the manufactures’ instructions.

Myocardial ischemia markers (CK-MB, troponin I) were measured before surgery as the baseline value (T0) and at the 6th and 12th...
postoperative hours after ICU arrival (T6 and T12, respectively). The CK-MB was measured by immuno inhibition assay (Anti CK-M. Immuno inhibition. Kinetic UV. Liquid. Bionik Diagnostic Systems, Tehran, Iran). On the other hand, troponin I was measured by chemiluminescence method (Ortho-clinical diagnostics a Johnson & Johnson company Vitros ECIQ immunodiagnostic, USA).

**Statistical Analysis**

Percentages were calculated for variables, whereas mean ± SD were expressed for the variables. One-way ANOVA followed by Tukey’s test was employed to investigate the mean difference between groups. Repeated measures of analysis of variance were also undertaken to investigate the mean differences of measured cardiac markers between the groups over time. All statistical analyses were performed using SPSS (version 11.5; SPSS Inc, Chicago, IL, USA). p values < 0.05 were considered statistically significant.

**Result**

**Baseline characteristic**

This study was performed in a tertiary University Hospital. The baseline characteristics and operative information are shown in Table 1.

Preoperative medication and existing comorbidities were comparable between the three groups. The perioperative management was similar in the groups, with no differences in duration of surgery, administration of blood products, and inotrope drugs. The volume of bleeding had no statistical difference between all groups. There was one reoperation for postoperative bleeding in every group. The three study arms did not show any statistically significant difference in the serum creatinine level at the first 3 days postoperatively. None of the patients receiving EPO experienced the potential adverse effects (hypertension crisis, MI, stroke and thromboembolic events) until discharge.

| Variable, unit of measurement | Group EPO-A (n = 35)   | Group EPO-CPB (n = 31) | Group P (n = 66) | P value |
|-------------------------------|------------------------|------------------------|------------------|---------|
| Age, years                    | 61.4 ± 10.1            | 60.4 ± 9.8             | 64 ± 9.5         | 0.34    |
| Hypertension, n (%)           | 26 (74.3)              | 24 (77.4)              | 19 (61.3)        | 0.32    |
| Diabetes mellitus, n (%)      | 13 (37.1)              | 11 (35.5)              | 12 (38.7)        | 0.96    |
| Hyperlipidemia, n (%)         | 22 (62.9)              | 20 (64.5)              | 16 (51.6)        | 0.52    |
| Previous myocardial infarction, n (%) | 17 (48.6) | 23 (74.2)              | 16 (51.6)        | 0.07    |
| Current smoking, n (%)        | 19 (54.3)              | 16 (41.9)              | 13 (45.2)        | 0.58    |
| Family history, n (%)         | 19 (48.6)              | 13 (74.2)              | 14 (51.6)        | 0.57    |
| Erythrocyte sedimentation rate, mm/h | 18.6 ± 12.7 | 19 ± 15.5              | 15.3± 13.7       | 0.53    |
| Ejection fraction, %          | 51 ± 10                | 47 ± 11.1              | 49± 9.5          | 0.43    |
| Aortic clamp time, minutes    | 48.4 ± 9.1             | 50.9 ± 1.6             | 47.3± 8.1        | 0.25    |
| Pump time, minutes            | 93.6 ± 19.2            | 99.7 ± 15              | 88.9± 16.4       | 0.06    |
| Bypass graft, n               | 3.25 ± 0.6             | 3.43 ± 0.7             | 3.16 ± 0.5       | 0.11    |
**Laboratory outcome**

The mean concentration of the markers in the successive measurements are presented in Table 2. The baseline level of following markers had no difference between the three study groups. In comparison with the baseline values, all markers had statistically significant changes by CPB effect.

**Pro-BNP**

The repeated measure test showed the mean pro-BNP level had a significant difference between groups over time ($p = 0.002$). The increase in pro-BNP level began 24 h after CPB in all groups. Group EPO-A had a lower mean level in comparison with group EPO-CPB ($p = 0.008$). There was no significant difference between group EPO-A and control ($p = 0.7$), and also between groups EPO-CPB and control ($p = 0.058$) at the first post operative day. One way ANOVA analysis revealed the mean level of pro-BNP in group

**Table 2.** The time courses of variation in the serum concentration of pro-BNP, CPK-MB and Troponin from baseline to postoperative period. Time points: T0 (before anesthesia induction), T1 (after protamine reversal), T2 (first postoperative day), T3 (second postoperative day), T6 and T12 (6 and 12 h) after ICU arrival. Data are means ± SD. For description of groups, please see the undernote of Table 1.

| Variable (unit of measurement) | Group EPO-A (n = 35) | Group EPO-CPB (n = 31) | Group P (n = 66) | $P$ value |
|-------------------------------|----------------------|------------------------|-----------------|-----------|
| CPK-MB (U/L)                  |                      |                        |                 |           |
| T0                            | 15 ± 5               | 13 ± 4                 | 18 ± 6          | 0.07      |
| T6                            | 33 ± 12              | 43 ± 17                | 42 ± 15         | 0.006     |
| T12                           | 37 ± 17              | 45 ± 15                | 53 ± 28         | 0.03      |
| Troponin (ng/mL)              |                      |                        |                 |           |
| T0                            | 0.26 ± 0.32          | 0.20 ± 0               | 0.32 ± 0.55     | 0.49      |
| T6                            | 4.80 ± 3.76          | 5.58 ± 8.92            | 5.83 ± 6.41     | 0.98      |
| T12                           | 7.84 ± 7.22          | 6.56 ± 6.14            | 8.25 ± 7.36     | 0.63      |
| Pro-BNP (pg/mL)               |                      |                        |                 |           |
| T0                            | 380 ± 718            | 551 ± 853              | 640 ± 887       | 0.31      |
| T1                            | 341 ± 623            | 556 ± 879              | 440 ± 622       | 0.26      |
| T2                            | 981 ± 1007           | 3030 ± 2991            | 1201 ± 630      | 0.000     |
| T3                            | 2209 ± 1717          | 3174 ± 3274            | 2362 ± 682      | 0.19      |
| YKL-40 (ng/mL)                |                      |                        |                 |           |
| T0                            | 56 ± 48              | 43 ± 39                | 60 ± 43         | 0.34      |
| T1                            | 64 ± 50              | 70 ± 60                | 62 ± 45         | 0.86      |
| T2                            | 326 ± 330            | 406 ± 90               | 358 ± 392       | 0.62      |
| T3                            | 252 ± 296            | 280 ± 200              | 128 ± 161       | 0.4       |
| IL-6 (pg/mL)                  |                      |                        |                 |           |
| T0                            | 1.5 ± 1.1            | 2.5 ± 1.3              | 2.4 ± 1.6       | 0.8       |
| T1                            | 64 ± 40              | 102 ± 49               | 49 ± 32         | 0.001     |
| T2                            | 23 ± 18              | 37 ± 42                | 19 ± 14         | 0.04      |
| T3                            | 8 ± 12               | 14 ± 22                | 8 ± 16          | 0.28      |

*Erythropoietin and Cardiac Biomarkers in CABG*
EPO-A was significantly lower than the other groups in the first postoperative day ($p < 0.001$) (Table 2).

**YKL-40**

After CPB, there was a mild increase in serum YKL-40. The peak level had a 24 h delay after operation and then decreased, but it did not return to basal laboratory range in 48 postoperative hours. Repeated measure test revealed serum YKL-40 had no significant difference between the groups over time ($p = 0.375$). Most of our patients had three vessel disease and the median serum YKL-40 in our study was 45(IQR: 23-68) ng/mL. There was a positive significant correlation between the number of diseased vessels and basal serum YKL-40 level ($p = 0.037$). Serum YKL-40 level in diabetic patients was higher than non-diabetic patients; however the difference was not significant (median (IQR):47.14 (17.55-59.03) ng/mL vs. 39.69 (23.63-72.81) ng/mL, $P = 0.813$).

**IL-6**

The serum IL-6 had significant difference between the groups after CPB ($p =0.001$ in T1 and $P =0.042$ in T2) (Table 2). *Post Hoc* test showed serum IL-6 in group EPO-CPB was significantly higher than in both group A and control in time T1 ($p = 0.001$ and $p = 0.001$, respectively). In time T2 there was a trend of increase in group EPO-CPB compared to control ($p =0.044$). Repeated measure test showed the serum IL-6 in group EPO-CPB was significantly higher than the other groups over time ($p = 0.001$ and $p = 0.001$, respectively).

**Cardiac enzymes**

All patients had an increase in postoperative CK-MB level. Repeated measure test showed the mean CK-MB level in group EPO-A was significantly lower than Placebo group ($P = 0.03$) and a trend for group EPO-CPB over time ($p = 0.058$). One-way ANOVA analysis showed a significant difference between study groups in T6 and T12 ($P=0.006$ and $P=0.038$, respectively). *Post Hoc* test showed mean CK-MB in group EPO-A was less than group EPO-CPB in T6 ($p=0.005$) and less than Placebo group in T12 ($p=0.035$). Although troponin I increased significantly in all groups, it had no significant difference between groups ($p = 0.8$). Table 2 depicts the postoperative level of cardiac enzymes and their changes.

**Secondary outcomes**

Postoperative AF was seen in all groups with no significant difference ($p =0.7$). Among measured markers, there was a correlation between AF and pro-BNP at first postoperative day ($P=0.025$). One-way ANOVA showed the ventilation time had a significant difference between groups ($p = 0.008$) (Table 3). *Post Hoc* test showed the ventilation time in group EPO-A was significantly lower than both groups EPO-CPB and Placebo ($p = 0.011$ and $p =0.041$, respectively). There was no significant difference in term of the need for blood transfusion between the groups during operation and ICU and the incidence of AKI (One patient in each EPO group and 2 patients in placebo grpoup). All the patients recovered well from their surgery without experience of EPO adverse effects.

EPO-A: 300 IU/Kg EPO diluted in isotonic saline as a total volume of 50 mL and was systemically infused through central venous line in the time interval started after induction of anesthesia and continued till the start of CPB; n = 35.

**Table 3. Postoperative data in 3 study groups.**

| Variable (unit of measurement) | Group EPO-A (n = 35) | Group EPO-CPB (n = 31) | Group P (n = 66) | $P$ value |
|-------------------------------|----------------------|------------------------|-----------------|----------|
| Bleeding (ml)                 | 440 ± 286            | 464 ± 194              | 513± 303        | 0.5      |
| PRBC(unit)                    | 0.5 ± 1.2            | 0.7 ± 0.8              | 0.6 ± 1.1       | 0.6      |
| AF (%)                        | 5(14%)               | 6(19%)                 | 5(16%)          | 0.7      |
| Time needed for Postoperative Mechanical Ventilation, hours | 7.2 ± 2.8            | 11.3 ± 6.7             | 10.7 ± 5.9      | 0.008    |

PRBC, packed red blood cell; AF, atrial fibrillation. For description of groups, please see the undernote of Table 1.
Erythropoietin and Cardiac Biomarkers in CABG

EPO-CPB: 300 IU/Kg EPO diluted in isotonic saline as a total volume of 50 mL and was systemically infused through central venous line in the time interval started just in the start of CPB and continued till aortic declamping; n = 31

P: a total volume of 50 ml isotonic saline was infused in the time interval started after induction of anesthesia and continued till aortic declamping; n = 66

Values in study groups are presented as mean ± SD.

Discussion

This study demonstrated EPO infusion has a significant immunomodulatory effect on inflammatory biomarkers in patients undergoing cardiac surgery with CPB especially when administered just after start of anesthesia and before going on bypass. A less significant effect is seen if EPO is started during CPB.

Based on previous studies and our knowledge, this is the first clinical trial to evaluate the serum level of inflammatory glycoprotein YKL-40 as a biomarker of inflammation in cardiac patients undergoing CABG; this could be a hallmark of our study (13, 14, 22-27).

YKL-40 (Chitinase-3-like Protein -1: a member of chitinase like proteins) is an inflammatory glycoprotein and a new biomarker of inflammation and cardiovascular disease (13, 22, 28). Besides, YKL-40 is an independent predictor or a prognostic biomarker of many cardiac events: coronary artery disease (CAD), number of diseased vessels, acute myocardial infarction (MI), angiographic lesion progression and cardiovascular mortality even in patients with stable CAD, fate of heart failure patients and overall mortality; also, statin treatment reduced serum YKL-40 level in CAD patients (13, 22, 25, 29-31).

Previous studies have shown a 24 h delay between the beginning of the major stress such as MI and the rise of serum YKL-40 level to its peak and then decrescendo trend over time (13, 25, 28). This was similar to our study: a mild increase in serum YKL-40 at the end of surgery and 24 h later, it peaked more than 7 times the baseline and then decreased. Similarly, YKL-40 level increased up to 7-fold in acute MI setting and 4-fold in chronic stable CAD (29, 32). Possibly the inflammatory response due to CPB is at least as potent as MI to provoke YKL-40 release. There is currently no data in other kinds of surgery assessing the trend of YKL-40.

The patients who received EPO before CPB (group EPO-A) had less serum levels of IL-6, pro-BNP, and CK-MB with shorter mechanical ventilation time compared with those who received EPO during CPB or the control group. However, perioperative EPO administration was not associated with improvement in nearly all of the post-operative outcome measures of the study, including need for blood transfusion, chest tube drainage, AF, and AKI; except the time for postoperative mechanical ventilation.

Correlation between YKL-40 and IL-6 has been investigated before. YKL-40 expression could be upregulated in hypoxia (25, 32-34). IL-6 might be a reliable marker of activated inflammatory cascade and mortality. However, the serum IL-6 was significantly higher in EPO-CPB group than the other groups over time, which might be due to the poor correlation between YKL-40 values and IL-6. Keeping in mind that activation of inflammatory response is an inevitable part of CPB, this finding could possibly stress on the more sensitive role of YKL-40 in detection of inflammation compared to IL-6; this is a relatively novel finding in our study mandating more complementary research (14, 23, 25, 35).

EPO has a number of anti-inflammatory effects as a pleiotropic cytokine, in addition to its well-known effect on erythropoiesis. Preclinical studies have indicated a broad variety of protective properties for EPO; however, when EPO has been used in clinical setting, controversial findings have been demonstrated regarding its potential anti-inflammatory and antioxidative effects (9, 10, 24, 26, 35-38).

Moreover, EPO has been used during myocardial reperfusion states (either through CABG or percutaneous coronary intervention: PCI) (17, 19, 20, 23-25, 27, 30, 32, 35, 39). The experimental models emphasize the importance of intervention time, possibly
due to narrow therapeutic EPO window. So, EPO administration before reperfusion injury (especially as short-term high dose EPO infusion) might be more effective with significant cardiac effects (9, 10, 19-21, 23, 24, 27, 29, 30, 36, 37, 39, 40). These studies support our findings in EPO-A group.

Our findings on CK-MB and troponin I were not supported by some other previous studies. Mocini et al. showed the failure of preoperative EPO to protect against ischemic reperfusion injury using CK-MB and troponin I peaks in the first three postoperative days (27). However, the possible explanation for our different results may be due to the prolonged (daily) intervals between their measurements. Besides, time to peak and return to the normal level for CK-MB is significantly lower than Troponin I. On the other hand, in our study, the response of pro-BNP to CPB was similar in all groups; the latter finding is in concordance with a number of previous studies (6, 8, 18, 35, 36, 41).

Our study could not demonstrate renal protective effects for EPO in cardiac surgical patients in contrast with some previous studies (19, 25). However, other results on this topic are somehow controversial which may be due to the enrollment of relatively few patients, different dosing and the timing of EPO administration in different studies (9, 10, 19, 32, 35, 36, 42, 43).

Limitation

several limitations of this study deserve mention. First, this was a single center study. We did not measure other inflammatory markers and had no long term follow up. The patient characteristics were similar in all groups, and our findings were rather homogeneous and uniform with relatively small power for external extrapolation. The serum level of the studied biomarkers was not corrected for hemodilution, though perioperative hemodilution was similar in all the patients. In addition, time points for collection of blood samples for analysis of inflammatory and cardiac markers were limited, and further measurement with closer intervals is suggested.

Conclusion

myocardial damage during CPB is multifactorial with several complex interactions and pathways. To the best of our knowledge, the present study is the first clinical study that shows the effect of EPO on inflammatory biomarker levels (especially YKL-40) during cardiac surgery with CPB. The extent of the inflammatory response induced by CPB is at least as potent as MI to evoke YKL-40 level. Serum YKL-40 reaches peak level one day after CPB. However, further studies are suggested to assess the efficacy and safety of the EPO treatment and the prognostic value of YKL-40 in the patients undergoing CABG with CPB.

Funding

the present study was supported by grants from the Research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran (no. 59658) and the Pooyesh Daru (no. 25957). The funders had no role in study design, data collection, statistical analysis, writing of the manuscript or decision to publish.

Acknowledgments

The authors thank biotechnician Saeed Azmdeh and research Nurse Sedigheh Zaker for their skillful technical support. We would like to thank Dr. Kheirabadi who kindly provided the epoietin alfa (PDpoetin) used in this study. This article has been extracted from the thesis written by Ms. Mohammadi (Registration No: 211).

References

(1) Aljure OD and Fabbro M, 2nd. Cardiopulmonary Bypass and Inflammation: The Hidden Enemy. J Cardiothorac. Vasc. Anesth. (2019) 33: 346-7.
(2) Heydarpour M, Ejjiofor J, Gilfeather M, Stone G, Gorham J, Seidman CE, Seidman JG, Yammime M, Body SC, Aranki SF and Muehlschlegel JD. Molecular Genetics of Lidocaine-Containing Cardioplegia in the Human Heart During Cardiac Surgery. Ann. Thorac. Surg. (2018) 106: 1379-87.
(3) Dabbagh A, Rajaei S, Bahadori Monfared A, Keramatinia AA and Omid K. Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions. Iran. J. Pharm. Res. (2012) 11: 705-14.
(4) Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW and Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies. J
Cardiothorac. Vasc. Anesth. (2009) 23: 384-93.
(5) Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, Darzi AW and Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 1—mechanisms of pathogenesis. J. Cardiothorac. Vasc. Anesth. (2009) 23: 223-31.
(6) Dabbagh A, Bastanifar E, Foroughi M, Rajaei S and Keramatinia AA. The effect of intravenous magnesium sulfate on serum levels of N-terminal pro-brain natriuretic peptide (NT pro-BNP) in elective CABG with cardiopulmonary bypass. J. Anesth. (2013) 27: 693-8.
(7) Aryana P, Rajaei S, Bagheri A, Karimi F and Dabbagh A. Acute Effect of Intravenous Administration of Magnesium Sulfate on Serum Levels of Interleukin-6 and Tumor Necrosis Factor-alpha in Patients Undergoing Elective Coronary Bypass Graft With Cardiopulmonary Bypass. Anesth. Pain Med (2014) 4: e16316.
(8) Foroughi M, Rahimian H, Dabbagh A, Majidi M, Hekmat M, Beheshti M and Shahzamani M. Postoperative N-terminal pro-brain natriuretic peptide level in coronary artery bypass surgery with ventricular dysfunction after perioperative glucose-insulin-potassium treatment. J. Cardiothorac. Vasc. Anesth. (2012) 26: 631-6.
(9) Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C and Lippi G. Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int. J. Cardiol. (2014) 171: 116-25.
(10) Talan MI, Ahmet I and Lakatta EG. Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window? PLoS One (2012) 7: e34819.
(11) Nairz M, Sonnweber T, Schroll A, Theur I and Weiss G. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes. Infect. (2012) 14: 238-46.
(12) Wood MA, Goldman N, DePierri K, Somerville J and Rigs JE. Erythropoietin increases macrophage-mediated T cell suppression. Cell Immunol. (2016) 306-307: 17-24.
(13) Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology (2012) 217: 483-91.
(14) Kjaergaard AD, Johansen JS, Bojesen SE and Nordestgaard BG. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Crit. Rev. Clin. Lab Sci. (2016) 53: 396-408.
(15) Ganem F, Serrano CV, Jr., Fernandes JL, Blotta MH, Souza JA, Nicolau JC, Ramires JAF and Hueb WA. Preoperative B-type natriuretic peptide, and not the inflammation status, predicts an adverse outcome for patients undergoing heart surgery. Interact Cardiovasc Thorac. Surg. (2011) 12: 778-83.
(16) Jogia PM, Kalkoff M, Sleigh JW, Bertinelli A, La Pine M, Richards AM and Devlin G. NT-pro BNP secretion and clinical endpoints in cardiac surgery intensive care patients. Anaesth. Intensive Care (2007) 35: 363-9.
(17) Litton E, Ho KM. The use of pre-operative brain natriuretic peptides as a predictor of adverse outcomes after cardiac surgery: a systematic review and meta-analysis. Eur. J. Cardiothorac. Surg. (2012) 41: 525-34.
(18) Fox AA, Sheman SK, Collard CD, Liu KY, Aranki SF, DeSantis SM, Jarolim P and Body SC. Preoperative B-type natriuretic peptide is an independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg (2008) 136: 452-61.
(19) Roubille F, Prunier F, Barrere-Lemaire S, Leclercq F, Piot C, Kritikou EA, Rheaume E, Busseuil D and Tardif JC. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. Cardiovasc. Drugs Ther. (2013) 27: 315-31.
(20) Prunier F, Biere L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, Charbonnier B, Genée O, Guérin P, Warin-Fresse K, Durand E, Lafont A, Christiansen L, Abi-Khalil W, Delépine S, Benard T and Furber A. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am. Heart. J. (2012) 163: 200-7.e1.
(21) Payani N, Foroughi M and Dabbagh A. The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial. Anesth Pain Med. (2015) 5: e22846.
(22) Arain F, Gulleslad T, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P and Ueland J. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosvastatin multinational trial in heart failure (CORONA). Biomarkers (2017) 22: 261-7.
(23) de Seigneur S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY and Saudan P. Epoetin administered after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol. (2012) 13: 132.
(24) Ferrario M, Arambitta E, Massa M, Rosti V, Marziliano N, Raineri C, Bertoletti A, De Ferrari GM, Klersy C, Angoli L, Bramucci E, Marzioni
patients with stable coronary artery disease. 

Foroughi M, Christiansen M, Johansen JS, et al. IJPR (2020), 19 (3): 430-439

(25) Harutyunyan M, Christiansen M, Johansen JS, Kober L, Torp-Petersen C and Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. *Immunobiology* (2012) 217: 652-6.

(26) Li J, Xu H, Gao Q and Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review. *Eur. J. Clin. Pharmacol.* (2012) 68: 469-77.

(27) Mocini D, Muso P, Guendouz E, De Marco L, Mele L, Cini R, Sordini P, Alois A, Costantino A, Arima S, Gentili C and Santini M. Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery. *Perfusion* (2008) 23: 187-92.

(28) Lin CH, Li HY, Jiang YD, Chang TJ and Chuang LM. Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with type 2 diabetes. *Clin. Endocrinol.* (Oxf). (2013) 79: 185-91.

(29) Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H and Gluud C, CLARICOR Trial Group. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. *Eur. Heart J.* (2009) 30: 1066-72.

(30) Harutyunyan M, Gotze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C and Kastrup J. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. *Immunobiology* (2013) 218: 945-51.

(31) Mygind ND, Iversen K, Kober L, Goetze JP, Nielsen H, Boesgaard S, M Bay, Johansen JS, Nielsen OW, Kirk V and Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. *J. Intern. Med.* (2013) 273: 205-16.

(32) Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA and Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. *Coron. Artery Dis.* (2008) 19: 257-63.

(33) Harutyunyan M, Johansen JS, Mygind ND, Reuter SB and Kastrup J. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. *Biomark. Med.* (2014) 8: 977-87.

(34) Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbrüchel DA, Friis T, Bindlev L, Haack-Sorensen M, Jørgensen E and Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. *Scand. Cardiovasc. J.* (2008) 42: 295-302.

(35) Poulsen TD, Andersen LW, Steinbruchel D, Gotze JP, Jørgensen OS and Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. *J. Cardiothorac. Vasc. Anesth.* (2009) 23: 316-23.

(36) Mastromarino V, Musumeci MB, Conti E, Tocci G and Volpe M. Erythropoietin in cardiac disease: effective or harmful? *J. Cardiovasc. Med. (Hagerstown).* (2013) 14: 870-8.

(37) Mastromarino V, Volpe M, Musumeci MB, Autore C and Conti E. Erythropoietin and the heart: facts and perspectives. *Clin. Sci. (Lond).* (2011) 120: 51-63.

(38) Koul D, Dhar S, Chen-Scarabelli C, Guglin M and Scarabelli TM. Erythropoietin: new horizon in cardiovascular medicine. *Recent Pat Cardiovasc Drug Discov.* (2007) 2: 5-12.

(39) Majidi TehraniMM and ForoughiM. Erythropoietin in the clinical trials of the cardiac disease, what is and what is not. *J. Cell Mol. Anesth.* (2019) 4: 136-44.

(40) Steppich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I. Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) Study Investigators. Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. *BMC Cardiovasc Disord.* (2017) 17: 38.

(41) Islamoglu F, Ozcan K, Apaydin AZ, Soydas C, Bayindir O and Durmaz I. Diagnostic accuracy of N-terminal pro-brain natriuretic peptide in the evaluation of postoperative left ventricular diastolic dysfunction. *Tex. Heart Inst. J.* (2008) 35: 111-8.

(42) Tasanarong A, Duangchana S, Sumransurp S, QC. Erythropoietin administration for prevention of cardiac disease-associated acute kidney injury: a meta-analysis of randomized controlled trials. *Eur. J. Cardiothorac. Surg.* (2015) 48: 32-9.

This article is available online at http://www.ijpr.ir

439